Trial Profile
A phase II trial of nilotinib in the treatment of c-KIT mutated advanced acral and mucosal melanoma (NICAM).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NICAM
- 31 Aug 2014 Accrual to date is 912% according to United Kingdom Clinical Research Network record.
- 21 Aug 2014 Status changed from recruiting to completed according to United Kingdom Clinical Research Network record.
- 21 Aug 2014 Accrual to date is 904% according to United Kingdom Clinical Research Network record.